Arrowhead Pharmaceuticals, Inc. (ARWR) Stock

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. is led by CEO Christopher R. Anzalone, employs 711 people, headquartered in Pasadena, US, publicly traded since 1993.

Arrowhead Pharmaceuticals, Inc. (ARWR) stock trades at $58.02 with a market capitalization of $8.20B. The stock is valued at a negative price-to-earnings (P/E) ratio of -28.66, reflecting a net loss over the last twelve months, price-to-book of 19.77, price-to-sales of 13.51. Over the past 52 weeks the stock has ranged between $34.61 and $95.49, and currently trades 39.2% below its 52-week high.

On profitability, Arrowhead Pharmaceuticals, Inc. generates a return on equity (ROE) of -60.54% (negative, reflecting a net loss), return on capital employed of -12.38%, an operating margin of 11.82%, a net profit margin of -47.79%.

Arrowhead Pharmaceuticals, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Arrowhead Pharmaceuticals, Inc. reported revenue of $0 rising to $829.0M. Compounded, revenue has grown 56.6% a year over five years, 50.5% over three, 20625.0% over the last twelve months. Net profit rose to $-2.0M.

Operating margin went from -51627.1% in 2016 to 11.9% in 2025, a gain of 51638.9 percentage points. The most recent net margin is -47.79%. On a trailing twelve-month basis to Jun '26, revenue is $669.0M and net profit $-320.0M.

Borrowings rose from $3.0M to $366.0M, cash from operations was $180.0M in the latest year, positive in 3 of the last 10.

Return on equity has averaged -95.7% over five years, and was -0.4% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Arrowhead Pharmaceuticals, Inc. (ARWR) — frequently asked questions